Frequency of nonmetastatic (physiological) uptake on posttreatment scans in patients with differentiated thyroid carcinoma

Endocrinologist

Volumn 17, Issue 2, 2007, Pages 78-82

  Souza Do Rosário, Pedro Weslley ^a,c   Barroso, Álvaro Luís ^b   Rezende, Leonardo Lamego ^b   Padrão, Eduardo Lanza ^b   Reis, Janice Sepulveda ^a   Purisch, Saulo ^a   Vasconcelos, Flávio Palhano ^a  

^a Endocrinology Service   (Brazil)

^b Nuclear Medicine Service   (Brazil)

^c Centro de Estudos e Pesquisa da Clinica de Endocrinologia e Metabologia CEPCEM   (Brazil)

Author keywords

False positive; Scanning; Thyroid cancer

Indexed keywords

IODINE 131; RADIOACTIVE IODINE; THYROGLOBULIN; THYROGLOBULIN ANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; ECHOGRAPHY; EOSINOPHILIC GRANULOMA; FALSE POSITIVE RESULT; FEMALE; HUMAN; HUMAN TISSUE; IODINE 131 UPTAKE TEST; MAJOR CLINICAL STUDY; MALE; METASTASIS; RADIOGRAPHY; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA; THYROIDECTOMY; TREATMENT OUTCOME; WHOLE BODY SCINTISCANNING;

EID: 34247149856     PISSN: 10512144     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ten.0000260858.92052.0b     Document Type: Article

References (44)

1. Dietlein M, Dressler J, Eschner W, et al. Procedures for iodine-131 whole body scintigraphy in the differential diagnosis of thyroid cancer. Nuklearmedizin. 1999;38:213-214.
2. McDougall IR. Whole-body scintigraphy with radioiodine-131: a comprehensive list of false-positives with some examples. Clin Nucl Med. 1995;20:869.
3. Sutter CW, Masilungan BG, Stadalnik RC. False-positive results of I-131 whole body scan in patients with thyroid cancer. Semin Nucl Med. 1995;25:279-282.
4. Wu SY, Brown T, Milne N, et al. Iodine-131 total body scan: extrathyroidal uptake of radioiodine. Semin Nucl Med. 1986;16:82-84.
5. Leitha TH, Staudenherz A. Frequency of diagnostic dilemmas in 131I whole body scanning. Nuklearmedizin. 2003;42:55-62.
6. Carlisle MR, Lu C, McDougall IR. The interpretation of 131I scans in the evaluation of thyroid cancer, with an emphasis on false positive findings. Nucl Med Commun. 2003;24:715-735.
7. Lind P. 131-I whole body scintigraphy in thyroid cancer patients. Q J Nucl Med. 1999;43:188-194.
8. 131I. J Nucl Med. 2000;41:1198-1202.
9. Rosario PW, Maia FF, Cardoso LD, et al. Usefulness of radioiodine scanning in patients with moderate/high risk differentiated thyroid carcinoma in whom thyroglobulin (without thyroxin) is undetectable after initial treatment. Arq Bras Endocrinol Metabol. 2004;48:384-388.
10. Pacini F, Capezzone M, Elisei R, et al. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab. 2002;87:1499-1501.
11. Feuerstein I, Harbert J. Hypertrophied thyroid tissue in a thyroglossal duct remnant. Clin Nucl Med. 1996;11:135.
12. Rieser G, Ober K, Cowan R, et al. Radioiodine imaging of struma cordis. Clin Nucl Med. 1998;13:421-422.
13. Yeh E, Meade R, Reutz P. Radionuclide study of struma ovarii. J Nucl Med. 1973;14:118-121.
14. Spitzweg C, Joba W, Eisenmenger W, et al. Analysis of human sodium/iodide symporter gene expression in extrathyroidal tissues and cloning of its complementary deoxyribonucleic acids from salivary gland, mammary gland, and gastric mucosa. J Clin Endocrinol Metab. 1998;83:1746-1751.
15. Hays M. Colonic excretion of iodide in normal human subjects. Thyroid. 1993;3:31-39.
16. Bestagno M, Pagliaini R, Maira G, et al. Mediastinal uptake of 131-I in patients with thyroid cancer: may it be referred to normal thymus [letter]? Eur J Nucl Med. 1993;20:648.
17. Davidson J, McDougall IR. How frequently is the thymus seen on whole-body iodine-131 diagnostic and post-treatment scans? Eur J Nucl Med. 2000;27:425.
18. Michigishi T, Mizukami Y, Shuke N. Visualization of the thymus with therapeutic doses of radioiodine in patients with thyroid cancer. Eur J Nucl Med. 1993;20:75-79.
19. Vermiglio F, Baudin E, Travagli J. Iodine concentration by the thymus in thyroid carcinoma. J Nucl Med. 1996;37:1830-1831.
20. Veronikis I, Simkin P, Braverman L. Thymic uptake of iodine 131 in the anterior mediastinum. J Nucl Med. 1996;37:991-992.
21. Wilson L, Barrington S, Morrison I, et al. Therapeutic implications of thymic uptake of radioiodine in thyroid carcinoma. Eur J Nucl Med. 1998;25:622-628.
22. Norby E, Neutze J, van Nostrand D, et al. Nasal radioiodine activity: a prospective study of frequency, intensity and pattern. J Nucl Med. 1990;31:52-54.
23. Park H, Wellman H. Hot nose after 131I sodium iodide thyroablation therapy. Clin Nucl Med. 1992;17:130-131.
24. Allen T, Wiest P, Vela S, et al. 131I Uptake in the breast for thyroid cancer surveillance with biopsy-proven benign tissue. Clin Nucl Med. 1998;23:585-587.
25. Bakheet SM, Hammami MM. Patterns of radioiodine uptake by the lactating breast. Eur J Nucl Med. 1994;21:604.
26. Bakheet S, Hammami M. False-positive radioiodine whole-body scans in thyroid cancer patients due to unrelated pathology. Clin Nucl Med. 1994;19:325.
27. Ibis E, Wilson C, Collier D. Iodine-131 contamination from thyroid cancer patients. J Nucl Med. 1992;33:2110-2115.
28. Brachman M, Rothman B, Ramanna L, et al. False-positive iodine-131 body scan caused by a large renal cyst. Clin Nucl Med. 1988;13:416.
29. Giuffrida D, Fornito M, Pellegriti G, et al. False positive 131-I total body scan due to bilateral polycystic renal disease. J Endocrinol Invest. 1997;20:342-344.
30. Garcia-Sanchis L, Lopez-Aznar D, Oltra A, et al. Metastatic follicular thyroid carcinoma to the kidney: a case report. Clin Nucl Med. 1999;24:48-50.
31. Rosenbaum R, Johnston G, Valente W. Frequency of hepatic visualization during I-131 imaging of metastatic thyroid carcinoma. Clin Nucl Med. 1988;13:657-660.
32. Zeissman H, Bahar H, Fahey F, et al. Hepatic visualisation on iodine-131 whole-body thyroid scan. J Nucl Med. 1987;28:1408-1411.
33. Chung JK, Lee YJ, Jeong JM, et al. Clinical significance of hepatic visualization on iodine-131 whole-body scan in patients with thyroid carcinoma. J Nucl Med. 1997;38:1191-1195.
34. Konez O, Hanelin L, Jenison E, et al. Functioning liver metastases on a whole-body scan: a case of malignant struma ovarii. Clin Nucl Med. 2000;25:465-466.
35. Schlumberger M, Baudin E. Serum thyroglobulin determination in the follow-up of patients with differentiated thyroid carcinoma. Eur J Endocrinol. 1998;138:249-252.
36. Rosario PW, Cardoso LD, Fagundes TA, et al. Revisiting the serum thyroglobulin in the follow-up of patients with differentiated thyroid carcinoma. Arq Bras Endocrinol Metabol. 2004;48:480-486.
37. Ozata M, Suzuki S, Miyamoto T, et al. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer. J Clin Endocrinol Metab. 1994;79:98-105.
38. Haugen BR, Pacini F, Reiners C, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab. 1999;84:3877-3885.
39. Mazzaferri EL, Robbins RJ, Spencer CA, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab. 2003;88:1433-1441.
40. Rosario PW, Maia FF, Fagundes TA, et al. Antithyroglobulin antibodies in patients with differentiated thyroid carcinoma: methods of detection, interference with serum thyroglobulin measurement and clinical significance. Arq Bras Endocrinol Metabol. 2004;48:487-492.
41. Rosario PW, Fagundes TA, Maia FF, et al. Sonography in the diagnosis of cervical recurrence in patients with differentiated thyroid carcinoma. J Ultrasound Med. 2004;23:915-920.
42. Robbins RJ, Chon JT, Fleisher M, et al. Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by self, to monitor for residual thyroid carcinoma? J Clin Endocrinol Metab. 2002;87:3242-3247.
43. Klutmann S, Jenicke L, Geiss-Tonshoff M, et al. Prevalence of iodineand thyroglobulin-negative findings in differentiated thyroid cancer: a retrospective analysis of patients treated from 1951 to 1998 in university hospital. Nuklearmedizin. 2001;40:143-147.
44. Rosario PW, Barroso AL, Padrao EL, et al. Clinical manifestations and diagnosis of distant metastases of differentiated thyroid carcinoma after initial therapy. Arq Bras Endocrinol Metabol. 2004;48:861-866.